| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Sera Prognostics, Inc. Class A Common Stock$1.75
-0.14 (-7.41%)
F 10Pipeline Score Tools & Services · Commercial
Market Cap
77.11 M
EPS
-0.67
P/E Ratio
-2.92 $
Value Trade
41.50 K
SEC Financials
Q1 2026Dilution Risk
25%Revenue
14.00 K
R&D Expenses
3.03 M
Operating CF
-8.77 M
Total Assets
93.54 M
Total Liabilities
25.92 M
Equity
67.62 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
47.40 M
Monthly Burn
2.92 M
Runway
14.8 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
87.46 K
52 Week Range
1.37 - 4.09
% held by Insiders
26.04 %
% held by Institutions
46.72 %
Enterprise Value
40.25 M
Total Shares
38.16 M
Short %
1.03 %
Float Shares
27.48 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F10
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 8%
Micro Cap (rank 834 of 905)
Percentile RankSera Prognostics, Inc. Class A Common Stock has significant pipeline risk (10/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SERA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
SERA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SERA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SERA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SERA Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
SERA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-06-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-06-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-06-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-SERA
Jun 1, 2026SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION
Sera Prognostics announced that Jeff Elliott will step down from its Board of Directors effective June 4, 2026. Elliott, who has been with the board since March 2025, cited increasing demands on his time as the reason for his departure. The company is actively seeking new board members to ensure leadership continuity.
Read more →-SERA
May 6, 2026SERA PROGNOSTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
Sera Prognostics reported its financial results for Q1 2026, highlighting a focus on commercial readiness and clinician engagement. The company published significant findings from the PRIME trial, showing its PreTRM test's effectiveness in reducing preterm births. Despite a decrease in revenue and a slight increase in net loss, Sera is actively expanding its partnerships and preparing for regulatory submissions in Europe.
Read more →-SERA
Apr 22, 2026SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026
Sera Prognostics Inc. has announced a conference call and webcast scheduled for May 6, 2026, to discuss its first quarter fiscal year 2026 financial results. The call will include operational highlights and a press release will be issued prior to the event. The company focuses on innovative pregnancy biomarker information to enhance maternal and neonatal health.
Read more →-SERA
Mar 4, 2026SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FOURTH QUARTER AND FISCAL YEAR 2025 FINANCIAL RESULTS ON MARCH 18, 2026
Sera Prognostics Inc. will report its fourth quarter and fiscal year 2025 financial results on March 18, 2026. A conference call and webcast will follow at 5:00 p.m. ET to discuss the results and operational highlights. The company aims to improve maternal and neonatal health through innovative pregnancy biomarker information.
Read more →-SERA
Feb 17, 2026SERA PROGNOSTICS TO PRESENT AT TD COWEN 46th ANNUAL HEALTH CARE CONFERENCE
Sera Prognostics Inc. will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026. The presentation will include a fireside chat discussing the company's latest achievements. Sera Prognostics aims to enhance maternal and neonatal health through its PreTRM Test, which predicts the risk of preterm birth.
Read more →Competitive Position
How SERA ranks across every disease it competes inCompetitive Position is a premium feature
See how SERA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial